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ESBLs among Klebsiella spp. ranged 
between 0.6% and 1.6%. In 2005 and 
2006, the rate of ESBL-producing 
Klebsiella spp. increased to 3.8% (44 
isolates) and 4.5% (55 isolates), re-
spectively, and originated mainly from 
intensive care units (Figure, panel B). 
In 2005, a single Klebsiella pneumoni-
ae isolate showed reduced susceptibil-
ity to imipenem (MIC 2 μg/mL) and 
to meropenem (MIC 4 μg/mL) and 
resistance to ertapenem (MIC >16 
μg/mL). Nevertheless, production of 
ESBL by Enterobacteriaceae organ-
isms is still rare in southeast Austria 
compared with other European coun-
tries (6). However, a dramatic increase 
of ESBL-producing E. coli and Kleb-
siella spp. has been observed during 
recent years. 
The increase of ESBL-producing 
E. coli isolates in outpatients with uri-
nary tract infections leads to serious 
treatment problems. Results from a 
recent study indicate that the increase 
of ESBL-producers in southeast Aus-
tria is caused mainly by the emer-
gence of CTX-M–type ESBLs, which 
are increasingly being isolated from 
outpatients (7). The K. pneumoniae 
isolate found in 2005 represents the 
ﬁ  rst ESBL-producing isolate not sus-
ceptible to carbapenems reported from 
Austria. Development of resistance 
to carbapenems in Enterobacteria-
ceae organisms has been reported in-
creasingly, which substantially limits 
treatment options for persons with 
multidrug-resistant gram-negative in-
fections (8).
Our data show insigniﬁ  cant 
changes in prevalence of MRSA and 
vancomycin-resistant enterococci 
in southeast Austria during the past 
decade but an alarming increase of 
multidrug-resistant ESBL-producing 
E. coli and Klebsiella spp. isolates in 
recent years. Detection of an ESBL-
producing K. pneumoniae isolate with 
reduced susceptibility to carbapenems 
shows that pathogens with new mech-
anisms of resistance are emerging in 
this region.
Alexandra Badura,* 
Gebhard Feierl,* 
Harald H. Kessler,* 
Andrea Grisold,* 
Lilian Masoud,* 
Ute Wagner-Eibel,* 
and Egon Marth*
*Medical University of Graz, Graz, Austria
References
  1.   World  Health  Organization.  Overcom-
ing antimicrobial resistance: world health 
report on infectious diseases 2000. [cited 
2006 June 16]. Available from http://www.
who.int/infectious-disease-report/2000/
other_versions/index-rpt2000_text.html
  2.   Clinical  Laboratory  Standards  Institute. 
Performance standards for antimicrobial 
susceptibility testing. Sixteenth infor-
mational supplement M100-S16. Wayne 
(PA): the Institute; 2006.
    3.   Tiemersma EW, Bronzwaer SL, Lyyti-
kainen O, Degener JE, Schrijnemakers P, 
Bruinsma N, et al. Methicillin-resistant 
Staphylococcus aureus in Europe, 1999–
2002. Emerg Infect Dis. 2004;10:1627–
34.
  4.   Witte W, Braulke C, Cuny C, Strommenger 
B, Werner G, Heuck D, et al. Emergence 
of methicillin-resistant Staphylococcus 
aureus with Panton-Valentine leukocidin 
genes in central Europe. Eur J Clin Micro-
biol Infect Dis. 2005;24:1–5.
  5.   Eisner A, Feierl G, Gorkiewicz G, Dieber 
F, Kessler HH, Marth E, et al. High preva-
lence of VanA-type vancomycin-resistant 
enterococci in Austrian poultry. Appl En-
viron Microbiol. 2005;71:6407–9.
    6.   Paterson DL, Bonomo RA. Extended-
spectrum β-lactamases: a clinical update. 
Clin Microbiol Rev. 2005;18:657–86.
  7.   Eisner A, Fagan EJ, Feierl G, Kessler HH, 
Marth E, Livermore DM, et al. Emergence 
of  Enterobacteriaceae isolates produc-
ing CTX-M extended-spectrum beta-lac-
tamase in Austria. Antimicrob Agents 
Chemother. 2006;50:785–7.
  8.   Nordmann P, Poirel L. Emerging carbap-
enemases in gram-negative aerobes. Clin 
Microbiol Infect. 2002;8:321–31.
Address for correspondence: Alexandra Badura, 
Institute of Hygiene, Medical University of 
Graz, Universitaetsplatz 4, 8010 Graz, Austria; 
email: alexandra.badura@meduni-graz.at
Osteomyelitis of 
Parietal Bone in 
Melioidosis 
To the Editor: In Europe and the 
United States, melioidosis is a rare 
disease, with no cases reported thus 
far from Slovenia. However, it is a 
relatively common disease in certain 
areas of Southeast Asia and northern 
Australia. Potentially fatal, this dis-
ease is caused by the gram-negative 
bacillus  Burkholderia pseudomallei, 
an environmental organism found in 
the soil and water of disease-endemic 
areas. Human infections are mostly ac-
quired through percutaneous inocula-
tion during contact with contaminated 
water and soil, although inhalation is 
also a recognized route of acquisition 
(1). Heavy monsoon rain is associated 
with severe disease course (2). Melioi-
dosis was reported in some persons in-
jured in the Tsunami in 2004 (3). The 
disease has a wide spectrum of signs 
and symptoms (4). Osteomyelitis is a 
rare manifestation. It occurs in <5% of 
cases and is a clinical challenge to di-
agnose and treat (1,4,5).
We describe a case of melioidosis 
in a previously healthy, 40-year-old 
Slovenian man. The patient had been 
working as a basketball trainer in Jor-
dan for the previous 12 months and 
was traveling to Brunei in mid-summer 
2006, 14 days before the illness start-
ed. While visiting Brunei, he sustained 
a minor head trauma when he hit his 
head on a night table at the hotel. Ten 
days later, high-grade fever up to 40°C 
developed, without any other signs or 
symptoms of disease. After returning 
to Jordan, the patient was admitted to 
a local hospital and received different 
antimicrobial agents without any im-
provement of his medical condition. 
After 6 weeks of unsuccessful treat-
ment, he decided to continue medical 
treatment in Slovenia.
On admission to our hospital, he 
reported headache and persistent high 
fever of 6 weeks’ duration. Physi-LETTERS
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cal examination indicated high fever 
(39.5°C) and occipital swelling with-
out any neurologic deﬁ   cits or other 
abnormal  ﬁ   ndings. Initial complete 
blood cell count, liver function test 
results, blood urea nitrogen levels, 
and creatinin levels were normal. C-
reactive protein was 60 mg/L, and 
erythrocyte sedimentation rate was 47 
mm/h. Results of chest radiograph and 
abdominal ultrasound were normal. 
Results of repeated blood cultures and 
urinalysis were negative. 
The suspected clinical diagnosis 
was brucellosis (the patient had eaten 
unpasteurized soft cheese during his 
stay in Jordan, and brucellosis is en-
demic in the Middle East). While wait-
ing for Brucella spp. tests, we began 
empirical antimicrobial drug treatment 
with doxycycline. The patient’s condi-
tion improved promptly. He became 
afebrile after 4 days of therapy. In the 
following week, ultrasound of occipi-
tal area soft tissue was performed, and 
posttraumatic seroma was diagnosed. 
B. pseudomallei was isolated from the 
seroma on sheep blood agar and iden-
tiﬁ   ed with VITEK 2 gram-negative 
identiﬁ  cation card (bioMérieux, Mar-
cy l’Etoile, France). The isolate was 
sensitive to piperacillin, piperacillin-
tazobactam, ceftazidime, imipenem, 
meropenem, and chloramphenicol. 
It was resistant to aminoglicosides 
(gentamicin, tobramycin, amikacin, 
netilmicin), colistin, and polymyxin 
B. Etest MIC showed susceptibility to 
doxycycline (MIC 2 μg/mL) and tri-
methoprim/sulfamethoxazole (TMP/
SMX) (MIC 1/19 μg/mL). Suscep-
tibility of B. pseudomallei to TMP/
SMX was tested with Etest because 
the disc-diffusion method is inappro-
priate and can overestimate the extent 
of resistance (6).
The patient later recalled going on 
a jungle trip in Brunei the day after his 
accident. During the trip, he scratched 
his head, and the skin started to bleed. 
Thus, he likely inoculated bacteria into 
the subcutaneous tissue of the head. 
Fever developed 10 days later.
Computed tomography of the 
scalp was performed (Figure), and os-
teomyelitis of the right parietal bone 
was detected. Magnetic resonance im-
aging (MRI) excluded involvement of 
intracranial tissues. Doxycycline was 
stopped and, as recommended, treat-
ment with ceftazidime and oral TMP/
SMX was started. The patient re-
ceived 8 weeks of intensive parenteral 
therapy. Once he was discharged, he 
received 4 months of oral eradication 
therapy with TMP/SMX and doxycy-
cline. The outcome was excellent. He 
is now without signs and symptoms 
of disease, has normal laboratory test 
results, and has no signs of inﬂ  amma-
tion on MRI.
Involvement of the skin and soft 
tissue is common in melioidosis (7). 
Osteomyelitis is a rare manifestation, 
usually part of a disseminated infec-
tion involving metaphyseal regions of 
long bones and vertebral bodies. Lo-
calized bone involvement is very rare 
(8). In a Thailand group of 21 patients 
with musculoskeletal melioidosis, all 
were initially treated with surgical de-
bridement, followed by long course 
of antimicrobial therapy (9). A single 
report of parietal bone osteomyeli-
tis was found in the literature; it was 
connected to a cerebral abscess due 
to hematogenous dissemination (10). 
Because of the speciﬁ  c location of the 
osteomyelitis (close to the leptomenin-
ges), nonextensive bone damage, and 
good initial response to antimicrobial 
therapy, we decided on conservative 
therapy only.
Melioidosis, although a rare dis-
ease, should be considered in the 
differential diagnosis of any febrile 
illness in patients returning from 
disease-endemic regions, especially 
Thailand and northern Australia. 
Without special awareness of this pos-
sibility, microbiologic laboratories in 
nonendemic regions could likely mis-
identify the bacteria and consequently 
misdiagnose the organism.
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Figure. Axial nonenhanced computed tomographic scan showing moth-eaten appearance 
of right parietal bone characteristic of osteomyelitis.LETTERS
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Chikungunya Fever, 
Andaman and 
Nicobar Islands, 
India
To the Editor: The outbreak of 
chikungunya fever that started in the 
Indian Ocean Islands in early 2005 
(1) spread through adjoining islands 
and appeared in peninsular India by 
late 2005 (2). It was ﬁ  rst noticed in 
the southern state of Andhra Pradesh 
in February 2006; it spread to Tamil 
Nadu in April 2006 and to Karnataka 
and Kerala in May. The western state 
of Gujarat also reported cases in April, 
but no cases were reported in May and 
June. The disease again reappeared 
in July and reached a peak in August. 
Later it affected the central Indian 
states of Maharashtra and Madhya 
Pradesh. In most states, the outbreak 
declined by October 2006 (3,4).
Andaman and Nicobar Islands, 
a union territory of India, is an ar-
chipelago of >500 islands and islets 
situated in the Bay of Bengal, 1,200 
km from peninsular India. People are 
constantly moving between mainland 
India and these islands. Chikungunya 
fever has previously not been reported 
from these islands.
During July and August 2006, 
medical professionals noticed an in-
crease in the number of cases of febrile 
illness in Port Blair, the headquarters 
of the union territory and the only ur-
ban area in the islands. The total num-
ber of patients with fever who visited 
the 5 urban health centers (UHC) in 
the town went up from the baseline of 
300–450 per day to 550–900 per day 
in July and August 2006. Most of the 
patients had associated joint pain. In 
view of the clinical features sugges-
tive of chikungunya fever, the ongoing 
epidemic on mainland India, and the 
widespread presence of the vector, Ae-
des aegypti, within the urban area of 
Port Blair (5), chikungunya fever was 
suspected. To conﬁ  rm this hypothesis, 
17 persons who fulﬁ  lled the case deﬁ  -
nition of having an acute febrile illness 
associated with severe pain in multiple 
joints were selected from among the 
initial patients who went to the UHCs 
and the referral hospital in Port Blair. 
Among these study participants, 15 
were adults and 2 were adolescents 
15 years of age; 6 were female and 11 
male. Four adults had febrile illness 
associated with joint pain; in these pa-
tients, weakness of all 4 limbs devel-
oped 3–15 days after onset of illness. 
All of the 4 patients with weakness 
had areﬂ  exic quadriplegia; 1 required 
ventilatory support. The patients with 
areﬂ   exic quadriplegia were treated 
with injections of methylprednisolone; 
all recovered within a week.
Blood samples were collected 
from these study participants. Serum 
samples were separated and sent to the 
National Institute of Virology, Pune, 
for detection of anti–chikungunya 
virus (CHIKV) immunoglobulin M 
(IgM) antibodies. Samples were col-
lected from 12 patients >4 days after 
the onset of symptoms. In the remain-
ing patients, the interval between onset 
of symptoms and collection of blood 
samples was <4 days. Of the 17 study 
participants, 13 were positive for anti-
CHIKV IgM antibodies. Three of 4 
samples that were negative for IgM 
antibodies to CHIKV were collected 
<3 days after the onset of symptoms. 
Among these, 2 samples were sub-
jected to reverse transcriptase–PCR 
by using the primers CHIKV/E1S (5′-
TAC CCA TTC ATG TGG GGC-3′) 
and CHIKV/E1C (5′-GCC TTT GTA 
CAC CAC GAT T-3′), as described by 
Hasebe et al. (6); both were positive 
for CHIKV RNA. All these samples 
were tested for dengue IgM antibod-
ies by using SD Bioline Dengue IgM 
Rapid Test (Standard Diagnostics Inc., 
Kyonggi-Do, South Korea), which 
uses a mixture of dengue recombinant 
envelop proteins and can detect all of 
the 4 dengue serotypes. None of the 
samples tested positive for dengue an-
tibodies. Hence, CHIKV infection was 
conﬁ  rmed in 15 of 17 patients.